/
Background Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis ( LN ).
37.06% operating margin is above average. ROIC at 14.89%.
Revenue up 20.4% YoY with margins expanding 39.1pp.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$298M
▲ +20.4% YoY
Net Income (TTM)
$298M
▲ +4893.1% YoY
Op. Margin
41.73%
▲ +39.1pp YoY
ROIC
18.27%
▲ +15.7pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
$167M
▲ +205.6% YoY
Net Debt
$28M
Cash & Equiv.
$41M
5Y CAGR: +41.4%
Continue Research